Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.60%. A quarter ago, it was expected that this company would post a loss of $0.87 per share when it actually produced a loss of $1.02, delivering a surprise of -17.24%.Over the last four quarters, the company ...